04Jul 2024
Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102)

Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102)

Relmapirazin, a fluorescent compound designed for point-of-care glomerular filtration rate (GFR) measurement, was validated in a clinical study involving 120 adults with varying chronic kidney disease stages. Compared to iohexol, relmapirazin showed excellent correlation (r²=0.99) and agreement in GFR measurement. Relmapirazin's GFR determination was unaffected by chronic kidney disease stage or race, with no severe adverse events reported, making it a viable GFR tracer in humans.

  • #nephrology

Like

Save

Share